Pravachol Sales Lag In Second Quarter; Bristol Pledges Continued Support
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb will continue to provide "strong support" for its cholesterol-lowering agent Pravachol (pravastatin) as a prescription therapy despite another quarter of declining sales as the drug approaches patent expiration in the U.S